This University of Washington/Fred Hutchinson Cancer Research Center CFAR proposal includes nine funded and six non-funded CFAR Cores. OAR lists 166 AIDS awards for over $36,000,000 to the UW & FHCRC. Funded Cores included A) Administration, providing financial administration and personnel management for approximately $14,000,000 in grants and contracts and 107 CFAR-affiliated staff, faculty and fellows; coordinates facilities and communications, administers a large charge-back cost center for computer graphics and slides (annual budget $160,000) and organizes Advisory Committee meetings. B) Developmental, which has funded 16 new investigators (9 have obtained grants, all continue in AIDS research); and will be enlarged to fund NIAs, and Emerging Opportunity Grants, and sponsor a CFAR Seminar Series. C) Biostatistics, providing the nucleus for coordination of a large UW HIV/AIDS biostatistics research effort, will strengthen support for behavioral and prevention research (and fund a behavioral prevention seminar series), as well as for health services and international research. D) Clinical Research, which previously initiated a primary infection clinic leading to a new NIH Acute Infections & Early Detection Network Award, and funded projects leading to two proposed cores; will continue support of clinical research infrastructure as well as pilot grants for clinical research. E) International began as a subcore of the CRC, and as a new Core will provide stable infrastructure support and fund research for emerging opportunities for many existing UW AIDS clinical and prevention projects in 11 developing countries, as well as for future sites. E) Health Services Research replaces the former AIDS Registry, shifting emphasis from cross-sectional epidemiology to prospective study of critical problems in health care delivery and outcomes research. G) Clinical Retrovirology already over subscribed will expand BL-3 space and introduce new technologies to meet steadily growing research demands. H) The new Molecular Diversity Core has attracted investigators locally and from throughout the US and other countries, introducing new genetic technologies and computational tools for viral sequencing and analysis. I) Molecular Immunology- at the forefront of development of methods for analyzing the cellular immune response - will introduce a peptide synthesis facility; a BL-3 flow cytometry/cell-sorting subcore; a humoral immunity subcore and a monoclonal antibody facility. All cores have oversight Core Committees, and most have core coordinator positions for supervision, and increased outreach. Nine new unfunded auxiliary CFAR cores include the Primate Center; General CRC; ACTU; AVEU; Primary Infection Clinic; Needle Exchange Evaluation Cohort, cohort of HIV sero-positive MSM in Seattle; and cohorts in Senegal & Kenya.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Center Core Grants (P30)
Project #
2P30AI027757-11
Application #
2595176
Study Section
Special Emphasis Panel (ZAI1-SCO-A (J1))
Project Start
1988-09-30
Project End
2003-02-28
Budget Start
1998-09-01
Budget End
1999-02-28
Support Year
11
Fiscal Year
1998
Total Cost
Indirect Cost
Name
University of Washington
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
135646524
City
Seattle
State
WA
Country
United States
Zip Code
98195
Olwit, Connie; Mugaba, Maureen; Osingada, Charles Peter et al. (2018) Existence, triggers, and coping with chronic sorrow: a qualitative study of caretakers of children with sickle cell disease in a National Referral Hospital in Kampala, Uganda. BMC Psychol 6:50
Young, J; Smith, C; Teira, R et al. (2018) Antiretroviral pill count and clinical outcomes in treatment-naïve patients with HIV infection. HIV Med 19:132-142
Heffron, Renee; Mugo, Nelly; Hong, Ting et al. (2018) Pregnancy outcomes and infant growth among babies with in-utero exposure to tenofovir-based preexposure prophylaxis for HIV prevention. AIDS 32:1707-1713
Torres, Thiago S; Harrison, Linda J; La Rosa, Alberto M et al. (2018) Quality of life among HIV-infected individuals failing first-line antiretroviral therapy in resource-limited settings. AIDS Care 30:954-962
Jiang, Wei; Luo, Zhenwu; Martin, Lisa et al. (2018) Drug Use is Associated with Anti-CD4 IgG-mediated CD4+ T Cell Death and Poor CD4+ T Cell Recovery in Viral-suppressive HIV-infected Individuals Under Antiretroviral Therapy. Curr HIV Res 16:143-150
Pyra, Maria; Brown, Elizabeth R; Haberer, Jessica E et al. (2018) Patterns of Oral PrEP Adherence and HIV Risk Among Eastern African Women in HIV Serodiscordant Partnerships. AIDS Behav :
LaCourse, Sylvia M; Cranmer, Lisa M; Bekker, Adrie et al. (2018) Symptom screening for active tuberculosis in pregnant women living with HIV. Cochrane Database Syst Rev 2018:
Edwards, Jessie K; Cole, Stephen R; Moore, Richard D et al. (2018) Sensitivity Analyses for Misclassification of Cause of Death in the Parametric G-Formula. Am J Epidemiol :
Wagner, Anjuli D; O?Malley, Gabrielle; Firdawsi, Olivia et al. (2018) Brief Report: Disclosure, Consent, Opportunity Costs, and Inaccurate Risk Assessment Deter Pediatric HIV Testing: A Mixed-Methods Study. J Acquir Immune Defic Syndr 77:393-399
Merlin, Jessica S; Long, Dustin; Becker, William C et al. (2018) Brief Report: The Association of Chronic Pain and Long-Term Opioid Therapy With HIV Treatment Outcomes. J Acquir Immune Defic Syndr 79:77-82

Showing the most recent 10 out of 1275 publications